Coagulopathy and severe bleeding are associated with high mortality. We evaluated haemostatic treatment guided by the functional viscoelastic haemostatic assays, thromboelastography or rotational thromboelastometry in bleeding patients. We searched for randomised, controlled trials irrespective of publication status, publication date, blinding status, outcomes published or language from date of inception to 5 January 2016 in six bibliographic databases. We included 17 trials (1493 participants), most involving cardiac surgery. Thromboelastography or rotational thromboelastometry seemed to reduce overall mortality compared to any of our comparisons (3.9% vs. 7.4%, RR (95%CI) 0.52 (0.28-0.95); I 2 = 0%, 8 trials, 717 participants). However, the quality of evidence is graded as low due to the high risk of bias, heterogeneity, imprecision and low event rate. Thromboelastography or rotational thromboelastometry significantly reduced the proportion of patients transfused with red blood cells (RR (95%CI) 
Introduction
Impaired haemostasis can contribute to intra-and postoperative bleeding and is associated with increased morbidity and mortality [1] . Transfusion of haemostatic blood products such as fresh frozen plasma, cryoprecipitate, platelets and clotting factor concentrates may be guided by clinical judgement, standard laboratory tests, thromboelastography (TEG) or rotational thromboelastometry (ROTEM), or a combination of these in transfusion algorithm. Generally, standard laboratory tests include activated partial thromboplastin time, prothrombin time, international normalised ratio (INR), platelet count and plasma fibrinogen. However, none of these tests were developed to predict bleeding or to guide coagulation management in the surgical setting [2] .
Thromboelastography and ROTEM are viscoelastic haemostatic assays [2] [3] [4] that provide a graphical evaluation of the kinetics of all stages of clot formation (initiation, propagation, strength and dissolution) in whole blood [2, 5] . Oozing is a very late clinical sign of coagulopathy. Management of massive transfusion therefore relies on simple, reliable and rapid diagnostic coagulation tests [1, 6] . Monitoring dynamic changes of haemostasis with TEG or ROTEM may enable: distinction between a surgical cause of bleeding or coagulopathy; diagnosis of the specific type of coagulopathic impairment; and guidance in the choice of haemostatic treatment. This may reduce the use of blood products and reduce bleeding, the need for re-operations and complications associated with hypovolaemic shock, and ultimately influence mortality.
The aim of this review was to assess the benefits and harms of a TEG-or ROTEM-guided transfusion in adults and children with bleeding. Furthermore, we conducted subgroup and sensitivity analyses, examined the role of bias and applied trial sequential analyses to evaluate the available amount of evidence.
Methods
This systematic review was carried out in accordance with Cochrane Collaboration methodology, PRISMA and GRADE guidelines [7] [8] [9] . This publication is an update of the existing Cochrane review with a preapproved and published protocol [10] .
We included parallel group, randomised and quasi-randomised, controlled trials irrespective of publication status, blinding status or language of the report. If necessary, we contacted the investigators and the authors in order to retrieve the relevant data. We only included unpublished trials if trial data and methodological descriptions were either provided in written form or could be retrieved from the authors. We excluded observational studies. We did not include any studies with non-standard designs, such as crossover trials or cluster-randomised trials. We included bleeding patients. We did not exclude any subgroup of the patient population.
We included trials of TEG-or ROTEM-guided transfusion algorithms. Interventional algorithms including TEG, ROTEM or both in combination with standard laboratory tests or other devices were also included. The primary analysis included trials on TEG or ROTEM vs. any comparator. We undertook separate subgroup analyses of trials in which a TEG-or ROTEM-guided transfusion algorithm was compared with clinical judgement, usual treatment or an algorithm based on standard laboratory tests: (i) TEG-or ROTEM-guided algorithm vs. any comparator; (ii) TEG-or ROTEM-guided algorithm vs. clinical judgement or usual treatment; (iii) TEG-or ROTEM-guided algorithm vs. a pre-defined algorithm based on standard laboratory tests; (iv) TEG or ROTEM in combination with standard laboratory tests or other devices in a guided algorithm vs. clinical judgement or usual care.
Our primary outcome was overall mortality (longest follow-up data from each trial regardless of the period of follow-up). Our secondary outcomes were: (i) bleeding events, blood loss, proportion of patients in need of transfusion and amount of blood products transfused; (ii) complications probably related to the underlying condition (infections, thrombosis, allergic reactions, congestive cardiac failure, myocardial infarction, renal failure, cerebrovascular accident); (iii) incidence of surgical intervention and re-operation due to bleeding; (iv) complications probably related to transfusion (infections and sepsis, haemolytic reactions and disseminated intravascular coagulation, major immunological and allergic reactions); (v) quality of life assessment, as defined by the authors of the included studies; (vi) duration of mechanical ventilation or improvement of respiratory failure (ventilator free days), or both; (vii) length of stay in the intensive care unit (ICU); (viii) number of days in hospital; (ix) cost-benefit analyses.
In [10] . We performed a systematic and sensitive search strategy to identify relevant randomised clinical trials with no language or date restrictions. For specific information regarding our search strategies please see Table S1 in Supporting Information Data S1. We re-ran the search on 5 January 2016. We hand searched the reference lists of reviews, randomised and non-randomised studies and editorials for additional studies. We contacted the main authors of studies and experts in this field to ask for any missed, unreported or ongoing studies. We contacted the manufactures of TEG and ROTEM and pharmaceutical companies for any unpublished trials (5 January 2016). We searched for ongoing clinical trials and unpublished studies on the following internet sites (search date 6 January 2016): ISRCTN registry; clinical trials registry; Center Watch; UMIN clinical trials registry. Two authors (AW and AA) independently evaluated all relevant trials. We also provided detailed description of our search results and resolved disagreements by discussion. We screened the titles and abstracts in order to identify eligible studies.
All trials were evaluated for major potential sources of bias (random sequence generation, allocation concealment, blinding, intention-to-treat analysis, funding and completeness of follow-up). We assessed each domain separately and in total grading each domain 'high risk', 'low risk' or 'unclear risk' of bias.
The degree of heterogeneity observed in the results was quantified using the I 2 statistic. We used trial sequential analysis to examine the required information size [11] . For more detailed information on statistical analyses and data management, assessment of risk of bias, subgroup and sensitivity analyses, assessment of heterogeneity, assessment of reporting biases and data synthesis including trial sequential analysis, see Supporting Information Data S1.
Results
Through electronic searches and from the references of potentially relevant articles, we identified 4484 (1924 in update) publications (Fig. 1) . We excluded 4415 publications as they were either duplicates or were clearly irrelevant. We retrieved a total of 69 (46 in update) relevant publications for further assessment. We included eight new trials to a total of 17 trials with a total of 1493 participants [12] [13] [14] [15] [16] [17] [18] [19] . Two trials contributed no data to the meta-analyses [15, 19] . All together, we statistically evaluated the results of 15 trials including 1185 patients in this systematic review. We found six ongoing trials but were unable to retrieve any data from the investigators at their current stage [20] [21] [22] [23] [24] [25] . The two review authors (AW, AFSH) completely agreed on the selection of included studies. We obtained additional information from the authors of six studies. A total of 17 trials [12] [13] [14] [15] [16] [17] [18] [19] [26] [27] [28] [29] [30] [31] [32] [33] [34] were included, of which two included only paediatric patients. The sample size varied from 28 participants to 224. One trial was conducted in a liver transplant setting [26] another in wound excisions of burns patients [17] , while the remaining trials (96% (1435) of included patients) were conducted in an elective cardiac surgery setting. The majority of studies applied the intervention algorithm intra-and postoperatively. Follow-up ranged from 24 hours to 3 years, but reports of six trials were unclear or did not provide data on the length of follow-up (Table 1) [12, 13, 15, [27] [28] [29] . Three [13, 16, 19] of the included studies were published only as abstracts and one [15] was terminated due to slow recruitment, but with no published results. There were no duplicate reports. Mortality was reported in eight studies [12, 14, 16, 18, 27, [29] [30] [31] . Four of the trials were stopped early due to either slow recruitment [13, 15, 16] or a positive interim analysis [18] . In 10 trials, the transfusion strategy in the control group was at clinicians' discretion in combination with standard laboratory tests [12, 17, 19, [27] [28] [29] [30] [31] [32] [33] . Seven trials compared TEG or ROTEM with a transfusion algorithm solely based on standard laboratory tests and without clinicians' discretion [13-16, 18, 26, 34] . Five trials used TEG or ROTEM in combination with other devices in the intervention group (see Table S2 in Supporting Information Data S1).
Only two trials [14, 31] could be classified as overall low risk of bias (Fig. 2) . Assessment is described in detail in Data S1.
Combining data from eight trials and applying complete case analysis showed a statistically significant effect of TEG-or ROTEM-guided algorithms vs. any comparison on longest follow-up mortality: 14/364 (3.9%) in the TEG/ROTEM group compared with 26/353 (7.4%) in the control group (RR (95%CI) 0.52 (0.28-0.95), I 2 = 0%) (Fig. 3) . This corresponds to a 48% relative risk reduction favouring a TEG-or ROTEM-guided transfusion. Two trials were zero event trials. [14, 29] . All trials except one [26] had point of hospital discharge as the longest follow-up.
However, due to the large distribution of the confidence interval, the substantial number of trials with high risk of bias and clinical heterogeneity involved, an exploratory analysis was carried out using a random effects model instead of the fixed effect model. Studies included in quanƟtaƟve synthesis (metaanalysis) (n = 15) Figure 1 Review flow diagram. *Excluded due to being clearly irrelevant, review, not randomised, no control group, animal studies, duplicate publication, thromboelastography or rotational thromboelastometry as a predictor or outcome or involving non-bleeding patients. (continued) no significant effect was identified for these outcomes ( Table 2 ). A total of 14 studies reported on the amount of pooled red blood cells. Four trials (29%) [14, 18, 28, 34] had a significant result all favouring the use of TEG-or ROTEM-guided transfusion. There was a substantial variation in the amount of blood transfused (see Table S3 in Supporting Information Data S1) even when excluding the two paediatric trials [12, 14] , the control group average varying between 1 and 17 units of pooled red blood cells given (see Table S4 in Supporting Information Data S1). In addition, many trials reported median and IQR, and attempts to calculate mean and standard deviation resulted in skewed data. This was equally the case for volume of fresh frozen plasma and platelets transfused (see Tables S5  and S6 in Supporting Information Data S1). More than half of the trials reporting on transfused amount of fresh frozen plasma showed a significant reduction favouring a TEG-or ROTEM-based transfusion algorithm. Two trials reported complete avoidance of fresh frozen plasma transfusion in the intervention group [17, 19] . Platelet transfusion amount was reported in 13 trials, with three [18, 27, 28] having a significant result indicating a reduced need of platelet transfusion favouring TEG-or ROTEM-guided transfusion. One trial [17] completely avoided platelet transfusion in the intervention group and one avoided platelet in the comparison group guided by standard laboratory tests and clinical judgement [32] . Only two studies transfused a mean/median amount of platelet of more than 2 units [26, 28] .
Meta-analysis of nine trials with a total of 90 events showed no reduction in surgical re-interventions (RR (95%CI) 0.75 (0.50-1.10), I 2 = 0%). Only two trials reported on bleeding events such as excessive bleeding events or massive transfusion [27, 30] with no difference between groups. The outcome of estimated bleeding showed substantial variation and skewed data (Table S3) , hence no meta-analysis was performed. Fourteen trials reported total bleeding volume; this varied from 390 ml to 6348 ml in the control groups with some trials reporting only perioperative bleeding, some postoperative and some both. Three trials had a significant result, all favouring a TEG-or ROTEM-guided transfusion strategy [14, 18, 28] . Only three studies had a mean/median blood loss in the control group exceeding 1000 ml [13, 16, 26] . Adverse events and complications were variably reported. The pooled intervention effect from three studies (200 patients) reporting on dialysis-dependent renal failure suggests a 54% relative risk reduction in favour of TEG-or ROTEM-guided transfusion strategy (RR (95%CI) 0.46 (0.28-0.76), I 2 = 0%). The difference in thrombotic events, surgical wound infection, postoperative acute respiratory distress, postoperative confusion and coagulopathy did not reach statistical significance. We were unable to conduct our analyses on transfusion-related complications (for example sepsis, haemolytic reactions, disseminated intravascular coagulation, major immunological and allergic reactions) since none of the trials provided information on these outcomes. Continuous outcomes such as time to extubation, length of stay in hospital or ICU, showed skewed data; thus no meta-analysis was performed (see Tables S7, S8 and S9 in Data S1). One study [12] reported a significantly reduced length of stay and three [12, 14, 18] reported a significantly reduced time in ICU and time to extubation. One trial provided data on cost-benefit [18] , but complete data were not available. Finally, none of the trials provided data on quality of life assessment. Trial sequential analysis of all trials of the effect of haemostatic transfusion guided by TEG or ROTEM on mortality (Fig. 4) showed that only 54% of the required information size (717 of 1325 patients) has been reached in a fixed effect model with continuity adjustment for zero event trials. However, only two trials had low risk of bias, with an insufficient event rate to carry out a separate meta-analysis. (Trial sequential analysis is ideally designed for trials with low risk of bias and is unable to adjust for risk of bias.) Trial sequential analysis with a random effects model resulted in a non-significant RR of 0.59 ((95%CI) (0.23-1.54), Diversity (D 2 ) = 0%, I 2 = 0%). Trial sequential analyses of dichotomous transfusion outcomes all suggest benefit when implementing a TEGor ROTEM-guided algorithm (see Figs. S1-S4 in Data S1). However, trial sequential analysis of low risk of bias trials showed insufficient information size for fresh frozen plasma and platelets. The comparisons TEG or ROTEM vs. clinical judgement or usual treatment; TEG or ROTEM vs. standard laboratory tests guided transfusion; and TEG or ROTEM in combination with standard laboratory tests or other devices in a guided algorithm vs. clinical judgement or usual care are described in Data S1.
Discussion
In this systematic review of 17 randomised trials involving 1493 patients with bleeding due to elective cardiac surgery, excision of burn wounds and liver transplantation, we found a 48% reduction in mortality with TEG-or ROTEM-guided blood transfusion. However, only eight trials provided data on mortality, two being zero-event trials; when we changed from a fixed model to random effects model for the meta-analysis, the statistical significance was no longer present. Additionally, trial sequential analysis suggests that only 54% of the required information size has been reached so far. Results on secondary outcomes showed a reduction in the need for blood transfusion. In general, studies included patients with low to moderate bleeding; only three studies had a mean/median blood loss in the control group exceeding 1000 ml. Three trials, all with moderate bleeding volume, showed a Figure 2 Review authors' judgements about risk of bias item for each included study. A green symbol denotes a low risk of bias for the domain in question; red and yellow symbols denote a high and unclear risk of bias, respectively. significant reduction in bleeding in favour of TEG or ROTEM. Two of these trials included patients with pathological or excessive postoperative bleeding [18, 28] . Our meta-analysis found no significant effect on the need for surgical re-intervention for bleeding. Overall, all analyses, whether significant or not, point towards a benefit of using a TEG-or ROTEM-guided transfusion. We did not perform meta-analysis on outcomes with skewed continuous data including bleeding volume, transfusion volume, duration of stay and ICU admittance and time to extubation. The total number of adverse events was few and this limits our ability to rule out any adverse effects. We found no significant adverse events except for a 54% reduced risk of dialysis-dependent renal failure. Only one study with unclear blinding found a reduced length of stay and three found a significantly reduced time in ICU and reduced time to extubation. We found six ongoing trials in an adult population of trauma, liver transplantation and elective cardiac surgery with bleeding, and an estimated population of 962 to be included, but we were unable to retrieve any information from investigators of most of the trials at the current stage [20] [21] [22] [23] [24] [25] . Our subgroup analysis comparing trials using TEG vs. ROTEM did not identify any difference between the two devices and large differences between trial algorithms were present. We were able to assess the subgroups comparing paediatric studies with adult and those using coagulopathy or excessive bleeding as inclusion criteria against those without, but found no significant subgroup effect.
The majority of trial patients included in this review (1435/1493, 96%) were elective cardiac surgery patients, of whom most were adults (1304/1435, 91%). This limits the external validity and a direct translation to other clinical settings should therefore be made with Figure 3 Forest plot of primary outcome: mortality at longest follow-up. great caution. In addition, our estimates of the required information size are not static and inclusion of trials with populations at high risk of bleeding and critically ill patients in settings such as sepsis, disseminated intravascular coagulation, trauma, obstetrics and transplantation may indeed alter our conclusions and estimates. The elective surgical setting of the included trials is far from the scenario of uncontrolled and sometimes undiagnosed life-threatening haemorrhage which usually characterises trauma, upper gastrointestinal bleeding or postpartum haemorrhage. No trials included in this review compare a TEG-or ROTEMguided treatment with a ratio-based 1:1:1 transfusion strategy [35] in cases of severe life-threatening haemorrhage, and therefore we are unable to make any conclusions as to the optimal strategy in these situations. One ongoing trauma study compares TEG-or ROTEM-guided treatment with an algorithm based on standard laboratory tests [23] , and one with a ratiobased transfusion of 1:1:1 between blood products (pooled red blood cell: fresh frozen plasma: platelets) [24] . We hope that results from these and future studies will shed some light on this discussion. Fibrinogen is the first coagulation factor to be depleted during ongoing bleeding [36] and three sources provide fibrinogen as a source for substitution therapy: fresh frozen plasma, cryoprecipitate and fibrinogen concentrate.
Ultimately an algorithm's ability to reduce fresh frozen plasma use might be caused by the preferred use of one of the other sources. Few trials reported cryoprecipitate or fibrinogen concentrate as the outcome (Table 1) . The use of massive transfusion protocols is generally advocated [37] as a tool for the team as well as the organisation to improve, standardise treatment and rehearse situations of ongoing severe bleeding. A team performs better with a clearly defined plan or treatment strategy. Therefore, one could argue that the effect of an unblinded comparison between a TEG-or ROTEM-guided treatment with loosely defined 'clinical decision based treatment' might just reflect the effect of having a clearly defined plan known by everyone in the team. In a post-hoc sensitivity analysis, we compared the included studies that compared TEG or ROTEM with clinical discretion, and those that compared it with another well-defined algorithm based on standard laboratory tests. No significant difference between these two groups was identified for our primary outcome, mortality, and the need for pooled red blood cells, but we found a p value of 0.05 for subgroup differences in the need for fresh frozen plasma, with a suggestion of greater efficacy in trials comparing TEG/ROTEM with clinical judgement or usual treatment as compared with those comparing with standard laboratory test-guided transfusion. Post-hoc analyses and multiple testing creates a high risk of bias, and should therefore be interpreted with great caution. Overall we believe that the effect of a TEG-or ROTEM-based treatment identified in this review is not just explained solely by the use of well-defined protocols.
In general, our review reaches the same conclusions as many of the included RCTs, many of the excluded trials and reviews. The NHS-funded Health Technology Assessment (HTA) review updated in 2015 [38] and published first in 2007 [39] focuses on three groups of patients, namely cardiac surgery, trauma and postpartum haemorrhage (obstetric bleeding). By including both RCTs and observational studies it aims to assess the effectiveness and cost-benefit of TEG/ROTEM. Our update includes another six RCTs not mentioned in the HTA report: Wang et al. [26] and Schaden et al. [17] include patients not covered by the report and NCT00772239 [15] has no published results. However, three studies had data on cardiac surgery patients [12, 13, 16] . They were published before the publication of the HTA review, but two are only published as abstracts [13, 16] and the last fulfils the inclusion criterion of being a trial assessing a TEG algorithm with a fibrinogen concentrate as part of the treatment in this algorithm. Our review finds the same suggestion of a reduced need for blood transfusion (pooled red blood cells, fresh frozen plasma or platelets), but in addition we have more data on mortality.
The HTA report uses random effect models in all analyses independent of I 2 -statistics [38] . It also concludes that TEG or ROTEM as an 'add-on' to a standard laboratory test-based protocol seems to be unsupported and therefore not recommendable from a cost-benefit point of view [38] . However, we did not identify any trial comparing TEG or ROTEM as an add-on to a standard laboratory test-guided algorithm with a group guided solely by standard laboratory tests (Table S2) . A systematic review published in 2013 [40] included 6835 participants across 12 studies, but most of the data were derived from one retrospective study and only 11% (749) from RCTs. Analyses were all together supportive of a TEG-or ROTEM-guided transfusion. This review did not provide additional information on side-effects or adverse events derived from the included observational studies. One additional Cochrane systematic review involving TEG or ROTEM [41] examined visco-elastic whole blood assays as a predictor of coagulopathy in trauma patients. Coagulopathy was defined using a reference standard of prothrombin time ratio and/or the international normalised ratio of 1.2 or greater, or 1.5 or greater. The aim was to evaluate the diagnostic test accuracy of TEG and ROTEM in trauma patients with clinically suspected coagulopathy and included crosssectional studies and case-control studies. No evidence on the accuracy of TEG and very little evidence on the accuracy of ROTEM were found, but this was undermined by a small number of included studies and risk of bias. Results of the present review assessing the interventional effect of haemostatic treatment guided by TEG or ROTEM are difficult to interpret in the context of the accuracy of which TEG or ROTEM predicts values of standard laboratory tests. A recently published systematic review with meta-analysis [42] addressed the possible beneficial effect of adding a platelet function test to the TEG-or ROTEM-guided algorithm specifically in cardiac surgery. The authors concluded that a significantly increased effect of adding the platelet function tests was found in regard to decrease in blood loss, reduction in the use of red blood cells and fresh frozen plasma, but with the opposite being the case for platelet transfusions. However, interpretation of the published meta-analyses reveals that this conclusion has been reached by comparing mean differences and relative risks of each subgroup and without addressing the fact that confidence intervals overlap between subgroup results, and the published test for subgroup differences was insignificant with no test of interaction carried out. Based on this and the results of the present review, we believe that there is currently no evidence to support the routine and systematic addition of a platelet function analyser to a TEG-or ROTEM-guided transfusion in cardiac surgery or any other type of surgical patients.
This systematic review with meta-analysis found indications of a reduced mortality and a reduction in the need for pooled red blood cells, platelets and dialysis-dependent renal failure. However, one has to exert great caution in interpreting benefits of TEG/ROTEM on mortality due to imprecision, inadequate information size (power) and the high proportion of trials with risk of bias. Large RCTs with low risk of bias are urgently needed to evaluate TEG and ROTEM in various clinical settings, populations and patients with massive transfusion requirements. Further trials need to focus on other relevant outcomes such as long-term survival adverse events and cost-benefit. The impact associated with the presence of coagulopathy or excessive bleeding also needs further exploration.
